RxDoctor Payments Data

William Rudy, OD

Optometrist · Kent, OHNPI 1972563047

Payments from drug & device makers

$1,956in general payments, 2019–2025

Across 76 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$336
  • AbbVie$320
  • Coopervision Inc.$167
  • Novartis$150
  • Regeneron Healthcare Solutions, Inc.$148
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$136
  • plus $697 from 18 others

What the payments were for

  • Speaking & faculty fees$181%
  • Food & beverage$1,93899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,956 in reported general payments places this provider in the 75th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$136,760
Medicare patients
746
Services billed
1,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost93$61,438
RestasisCyclosporine45$58,032
RocklatanNetarsudil Mesylat/Latanoprost15$10,039
Brimonidine Tartrate166$9,037
Travoprost42$7,630
RhopressaNetarsudil Mesylate20$7,524
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$7,355
Latanoprost464$7,266
Alphagan PBrimonidine Tartrate17$6,982
Cyclosporine11$5,968
Prednisolone Acetate115$5,070
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat190$3,165
Bimatoprost18$2,310
Fluorometholone29$2,273
Loteprednol Etabonate14$2,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$320$126,452155 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$15$17,56335 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$136$2,04414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Kent

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →